医药生物行业双周报：《中国新药注册临床试验进展年度报告（2023年）》发布，2024年医药集中采购提质扩面

Investment Rating - The industry investment rating is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 5.78%, ranking 30th among 31 primary industries, underperforming the CSI 300 index which fell by 1.77% [6][14] - The overall PE (TTM) for the pharmaceutical and biotechnology industry as of May 24, 2024, is 26.43x, down from 27.90x in the previous period, indicating a downward trend in valuation [18] - In 2023, the number of new drug clinical trials registered in China reached 2,323, a year-on-year increase of 14.3%, with 1,606 trials classified as Class 1 drugs, accounting for 69.1% of the total [8][22] Industry Review - The decline in the pharmaceutical and biotechnology industry index was primarily driven by offline pharmacies and medical devices, which saw declines of 2.19% and 2.97%, respectively, while other biological products and medical consumables experienced increases of 8.09% and 7.81% [6][14] - As of May 24, 2024, the PE (TTM) for the pharmaceutical industry is 26.43x, with the highest valuations in diagnostic services (58.67x), hospitals (37.66x), and medical consumables (35.24x), while pharmaceutical distribution has the lowest valuation at 15.87x [18] Important Industry News - The CDE released the "Annual Report on the Progress of New Drug Registration Clinical Trials (2023)" [7] - The National Medical Insurance Administration emphasized strengthening regional collaboration for the improvement and expansion of centralized pharmaceutical procurement in 2024 [24] - Innovative drugs approved in 2023 include 40 new drugs, with domestic marketing authorization holders accounting for over 90% [22][23] Investment Recommendations - Continuous attention is recommended for companies in the pharmaceutical sector that have surpassed performance inflection points and exhibit strong profitability [9]